Patent · US Active

Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)

US11071726B2 · kind B2 · utility

5Cited by

65References

21Claims

0Family size

Assignee

IPSEN BIOPHARM LIMITED · GB

Inventors

Jonathan Basil Fitzgerald · Arlington, US
Ashish Kalra · Belmont, US
Shannon Leonard · Hamilton, US
Stephan Braun · Paris, FR
Bin Zhang · Beijing, CN

Key dates

Filing date	Nov 1, 2017
Grant date	Jul 27, 2021
Priority date	—
Expiry date	Nov 1, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of gastric cancer, including treatment of patients diagnosed with previously untreated gastric cancer. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.